Paul J. Gilligan - Concepedia

Author

Paul J. Gilligan

Bristol-Myers Squibb (United States)

Also Known As

Gilligan, P.J., P Gilligan, P J Gilligan, P. J. GILLIGAN, Paul Gilligan, Paul J Gilligan, Paul J. Gilligan

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (United States)Wilmington University Experimental Station DuPont (United States)Bristol-Myers Squibb (Germany)

About

Paul J. Gilligan is an author at Bristol-Myers Squibb (United States) specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	17	24	887
2	Natural Sciences	10	10	451
3	Social Sciences	6	6	229
4	Engineering	1	1	47
5	Public Health	1	1	55

Paul J. Gilligan

Publications

1.4K

Citations

H-Index

Page 1

	Year	Citations
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2,4-dichlorophenyl)pyrazolo[1,5-<i>a</i>]-1,3,5-triazine: A Potent, Orally Bioavailable CRF<sub>1</sub> Receptor Antagonist Liqi He, Paul J. Gilligan, Robert Zaczek, Journal of Medicinal Chemistry Receptor AntagonistPharmacotherapyPharmaceutical ChemistryMolecular PharmacologyMedicinal Chemistry	2000	113
The discovery of 4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine: A corticotropin-releasing factor (hCRF1) antagonist Paul J. Gilligan, Caryn Baldauf, Anthony J. Cocuzza, Bioorganic & Medicinal Chemistry	2000	83
Non-Peptide Corticotropin-Releasing Hormone Antagonists: Syntheses and Structure−Activity Relationships of 2-Anilinopyrimidines and -triazines Argyrios G. Arvanitis, Paul J. Gilligan, Robert J. Chorvat, Journal of Medicinal Chemistry	1999	74
Use of the suzuki reaction for the synthesis of aryl-substituted heterocycles as corticotropin-releasing hormone (CRH) antagonists Anthony J. Cocuzza, Dennis R. Chidester, Steven Culp, Bioorganic & Medicinal Chemistry Letters Suzuki ReactionMedicinal ChemistryHeterocyclicBiochemistryCorticotropin-releasing Hormone	1999	72
Corticotropin-Releasing Hormone Receptor Antagonists: Framework Design and Synthesis Guided by Ligand Conformational Studies C. Nicholas Hodge, Paul E. Aldrich, Zelda R. Wasserman, Journal of Medicinal Chemistry Crh1 Receptor AntagonistsReceptor-bound ConformationChemical BiologyMolecular PharmacologyMedicinal Chemistry	1999	69
Novel piperidine .sigma. receptor ligands as potential antipsychotic drugs Paul J. Gilligan, Gary A. Cain, Thomas E. Christos, Journal of Medicinal Chemistry Molecular PharmacologyPsychoactive DrugSigma ReceptorPsychiatrySigma Sites	1992	66
Synthesis, Corticotropin-Releasing Factor Receptor Binding Affinity, and Pharmacokinetic Properties of Triazolo-, Imidazo-, and Pyrrolopyrimidines and -pyridines Robert J. Chorvat, Rajagopal Bakthavatchalam, James P. Beck, Journal of Medicinal Chemistry	1999	63
Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands Richard A. Hartz, Argyrios G. Arvanitis, Charles R. Arnold, Bioorganic & Medicinal Chemistry Letters Combinatorial ChemistryMolecular PharmacologyMedicinal ChemistryBiochemistryMedicine	2005	63
Receptor Occupancy of Nonpeptide Corticotropin-Releasing Factor 1 Antagonist DMP696: Correlation with Drug Exposure and Anxiolytic Efficacy Yu-Wen Li, Geraldine Hill, Harvey Wong, Journal of Pharmacology and Experimental Therapeutics	2003	60
Synthesis and Structure−Activity Relationships of 8-(Pyrid-3-yl)pyrazolo[1,5-<i>a</i>]-1,3,5-triazines: Potent, Orally Bioavailable Corticotropin Releasing Factor Receptor-1 (CRF<sub>1</sub>) Antagonists Paul J. Gilligan, Todd Clarke, Liqi He, Journal of Medicinal Chemistry Receptor AntagonistsPsychopharmacologyCompound 13-15PharmacotherapyHeterocycle Chemistry	2009	58

Page 1